Roche’s Columvi Approval By US FDA Takes Bispecific Antibodies Into Fixed-Duration Therapy

 
• By Bridget Silverman
  
bridge
Columvi takes bispecific antibody treatment to new places. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers